Reaction Biology is a preclinical oncology CRO offering a comprehensive portfolio of in vivo services for testing of new anti-cancer drugs. Our integrated cancer drug testing platform includes services for all steps of the drug discovery process, supporting the development of your preclinical candidate pipeline.
The premises of our CRO feature a state-of-the-art animal facility is located in Germany. All of our in vivo services are conducted under GV-SOLAS and ISO9001 in regard to standards of animal welfare and code of practice.
You will be guided by an assigned in vivo project manager throughout all phases of the study - layout, protocol, conduction, results. Before, during, and after the study, your project manager will be just one phone call away for any questions you may have. Accountability and reproducibility are the fundaments of the high quality of our in vivo pharmacology.
Human xenograft tumor models are the most frequently used in vivo models for the evaluation of the therapeutic effects of novel anti-cancer drug candidates, including subcutaneous, subQperior, orthotopic, and metastasis models.
The In Vivo Hollow Fiber Model is an efficient and economic screening approach which is used for two purposes: (i) Select the compound with the best in vivo activity ("compound screening"), or (ii) identify a suitable tumor cell line for in vivo efficacy studies ("tumor model screening")
Genetically engineered tumor models are well suited for the investigation of a single driver of tumor growth such as an overexpressed or constitutively expressed kinase.
PK and PD Studies
Reaction Biology supports clients with pharmacokinetic (PK) and pharmacodynamic (PD) studies to understand the interaction of the drug and body.
Maximum Tolerated Dose
Determining the maximum tolerated dose (MTD) is the first step when taking a new drug candidate from in vitro to in vivo phase. The MTD study examines potential toxicities and enables efficacy testing of novel substances with the highest possible dose.